NO20062081L - Fremgangsmate - Google Patents

Fremgangsmate

Info

Publication number: NO20062081L
Authority: NO; Norway
Prior art keywords: immunization; administration; patient; cell epitope; days
Prior art date: 2003-10-10

Application number

NO20062081A

Other languages

English (en)

Norwegian (no)

Inventor

Ralph Patrick Braun

Lichun Dong

Original Assignee

Powderject Vaccines Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-10

Filing date

2006-05-09

Publication date

2006-06-20

2006-05-09 Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc

2006-06-20 Publication of NO20062081L publication Critical patent/NO20062081L/no

Links

230000003053 immunization Effects 0.000 abstract 4
238000002649 immunization Methods 0.000 abstract 4
210000001744 T-lymphocyte Anatomy 0.000 abstract 3
238000000034 method Methods 0.000 abstract 2
230000005867 T cell response Effects 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Oncology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)

NO20062081A 2003-10-10 2006-05-09 Fremgangsmate NO20062081L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US51008603P	2003-10-10	2003-10-10
US52657103P	2003-12-04	2003-12-04
US56777104P	2004-05-05	2004-05-05
PCT/US2004/033391 WO2005035779A2 (en)	2003-10-10	2004-10-12	Method

Publications (1)

Publication Number	Publication Date
NO20062081L true NO20062081L (no)	2006-06-20

Family

ID=34437668

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20062081A NO20062081L (no)	2003-10-10	2006-05-09	Fremgangsmate

Country Status (15)

Country	Link
US (1)	US20070026015A1 (de)
EP (1)	EP1675596A4 (de)
JP (1)	JP2007508319A (de)
KR (1)	KR20060123138A (de)
CN (1)	CN1889963A (de)
AU (1)	AU2004280630A1 (de)
BR (1)	BRPI0415202A (de)
CA (1)	CA2542295A1 (de)
EA (1)	EA012066B1 (de)
IL (1)	IL174849A0 (de)
MX (1)	MXPA06003977A (de)
NO (1)	NO20062081L (de)
NZ (1)	NZ547042A (de)
SG (1)	SG146662A1 (de)
WO (1)	WO2005035779A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005035771A2 (en)	2003-10-10	2005-04-21	Powderject Vaccines, Inc.	Nucleic acid constructs
US9090673B2 (en) *	2003-12-12	2015-07-28	City Of Hope	Synthetic conjugate of CpG DNA and T-help/CTL peptide
GB0507997D0 (en) *	2005-02-01	2005-05-25	Powderject Vaccines Inc	Nucleic acid constructs
DK1907000T4 (da)	2005-06-08	2020-03-30	The President And Fellows Of Harvard College	Fremgangsmåder og sammensætninger til behandling af persisterende HIV-infektioner ved hæmning af reaktionsvejen for programmeret celledød 1 (PD-1).
EP1934246B8 (de)	2005-10-07	2012-02-08	Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L.	Matrixmetalloproteinase-11-impfstoff
US7628993B2 (en)	2006-07-20	2009-12-08	Vical Incorporated	Compositions and methods for vaccinating against HSV-2
CA2673870A1 (en) *	2006-12-27	2008-07-10	Emory University	Compositions and methods for the treatment of infections and tumors
EP2044949A1 (de)	2007-10-05	2009-04-08	Immutep	Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
WO2009127666A2 (en) *	2008-04-15	2009-10-22	Glaxosmithkline Biologicals S.A.	Method and compositions
MX2011005691A (es)	2008-11-28	2011-07-20	Univ Emory	Metodos para el tratamiento de infecciones y tumores.
BRPI1009892A2 (pt) *	2009-03-24	2016-03-15	Transgène S A	método ex-vivo para avaliar a eficácia de um tratamento em um paciente, e, kit para testar se um paciente está respondendo terapeuticamente a um método de tratamento compreendendo administração de uma composição imunogênica
WO2014150179A1 (en) *	2013-03-15	2014-09-25	Rush University Medical Center	Pseudomonas exotoxins for cancer treatment
GB201322626D0 (en)	2013-12-19	2014-02-05	Immutep S A	Combined preparations for the treatment of cancer
MA40783A (fr) *	2014-10-03	2017-08-08	Los Alamos Nat Security Llc	Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
GB201500374D0 (en)	2015-01-09	2015-02-25	Immutep S A	Combined preparations for the treatment of cancer
DK3294326T3 (da)	2015-05-15	2021-05-31	Curevac Ag	Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5593972A (en) *	1993-01-26	1997-01-14	The Wistar Institute	Genetic immunization
US6183746B1 (en) *	1997-10-09	2001-02-06	Zycos Inc.	Immunogenic peptides from the HPV E7 protein
AU765940B2 (en) *	1998-06-24	2003-10-02	Innogenetics N.V.	Particles of HCV envelope proteins: use for vaccination
EP1200459B1 (de) *	1999-07-12	2007-11-21	Genesis Research & Development Corporation Limited	Verbindungen zur behandlung von infektionskrankheiten und störungen des immunsystems sowie methoden ihrer anwendung
WO2002011748A1 (en) *	2000-08-07	2002-02-14	Sloan-Kettering Institute For Cancer Research	Method and composition for immunization using mixed pools of mutated nucleic acids or peptides
CA2422524A1 (en) *	2000-09-25	2002-03-28	Motoyuki Yamashita	Pei: dna vector formulations for in vitro and in vivo gene delivery
GB0206461D0 (en) *	2002-03-19	2002-05-01	Glaxo Group Ltd	Improvements in vaccination
US20050266024A1 (en) *	2002-03-19	2005-12-01	Powdermed Limited	Adjuvant
US20030190308A1 (en) *	2002-03-19	2003-10-09	Braun Ralph P.	Adjuvant
AU2003216851B2 (en) *	2002-03-19	2008-04-17	Powderject Research Limited	Imidazoquinoline adjuvants for vaccines

2004
- 2004-10-12 WO PCT/US2004/033391 patent/WO2005035779A2/en not_active Ceased
- 2004-10-12 MX MXPA06003977A patent/MXPA06003977A/es not_active Application Discontinuation
- 2004-10-12 CN CNA2004800364591A patent/CN1889963A/zh active Pending
- 2004-10-12 EP EP04794672A patent/EP1675596A4/de not_active Withdrawn
- 2004-10-12 NZ NZ547042A patent/NZ547042A/en unknown
- 2004-10-12 JP JP2006534429A patent/JP2007508319A/ja not_active Withdrawn
- 2004-10-12 AU AU2004280630A patent/AU2004280630A1/en not_active Abandoned
- 2004-10-12 SG SG200806935-3A patent/SG146662A1/en unknown
- 2004-10-12 CA CA002542295A patent/CA2542295A1/en not_active Abandoned
- 2004-10-12 KR KR1020067009022A patent/KR20060123138A/ko not_active Ceased
- 2004-10-12 EA EA200600738A patent/EA012066B1/ru not_active IP Right Cessation
- 2004-10-12 BR BRPI0415202-6A patent/BRPI0415202A/pt not_active IP Right Cessation
- 2004-10-12 US US10/574,922 patent/US20070026015A1/en not_active Abandoned
2006
- 2006-04-06 IL IL174849A patent/IL174849A0/en unknown
- 2006-05-09 NO NO20062081A patent/NO20062081L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2542295A1 (en)	2005-04-21
KR20060123138A (ko)	2006-12-01
WO2005035779A2 (en)	2005-04-21
EP1675596A2 (de)	2006-07-05
JP2007508319A (ja)	2007-04-05
BRPI0415202A (pt)	2006-12-05
EA200600738A1 (ru)	2006-10-27
EP1675596A4 (de)	2009-01-21
IL174849A0 (en)	2008-02-09
WO2005035779A3 (en)	2005-07-14
NZ547042A (en)	2010-05-28
US20070026015A1 (en)	2007-02-01
EA012066B1 (ru)	2009-08-28
MXPA06003977A (es)	2006-06-27
CN1889963A (zh)	2007-01-03
AU2004280630A1 (en)	2005-04-21
SG146662A1 (en)	2008-10-30

Legal Events

Date	Code	Title	Description
2011-05-30	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
BRPI0315228A8 (pt)	2018-04-03	Vacinas de polipeptídeo para ampla proteção contra linhagens meningocócicas hipervirulentas
DK0853487T3 (da)	2000-10-23	Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus
ATE430207T1 (de)	2009-05-15	Genomische sequenzen von neisseria und verfahren zu ihrer verwendung
NO20071609L (no)	2007-06-18	Immunogen sammensetning for anvendelse ved vaksinering mot stafylokokker
NO20070618L (no)	1998-04-27	Forbindelser og fremgangsmater for immunterapi og diagnose av tuberkulose.
EP1144998A3 (de)	2002-08-07	Genomische sequenzen von neisseria und verfahren zu ihrer verwendung
AU2003244855A1 (en)	2004-01-23	Method to enhance an immune response of nucleic acid vaccination
NO950881D0 (no)	1995-03-07	Nöytraliserende monoklonale menneske-antistoffer mot andedretts-syncytial-virus
BRPI0414443A (pt)	2006-11-21	imunógenos consensuais/ancestrais
SG146662A1 (en)	2008-10-30	Method
NO341586B1 (no)	2017-12-11	Fremgangsmåte for valg av et anti-naturlig drepe cellereseptor (NKR) antistoff
ES8801318A1 (es)	1987-12-16	Un procedimiento para la produccion de un peptido.
NO20026121L (no)	2003-02-13	Streptokokkantigener
WO1997003203A3 (en)	1997-04-17	Generation of immune responses to prostate-specific antigen (psa)
WO2003082183A3 (en)	2004-01-15	Protein-based streptococcus pneumoniae vaccines
Nolan et al.	2015	Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults
NO20081043L (no)	2008-04-07	Vaksine for fisk
DK0880360T3 (da)	2003-01-27	Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop
Flitter et al.	2025	An oral norovirus vaccine tablet was safe and elicited mucosal immunity in older adults in a phase 1b clinical trial
Lu et al.	2021	Novel vaccine design based on genomics data analysis: A review
NO971768L (no)	1997-06-03	Hemoglobinreseptorer fra Neisseriae
DK0852623T3 (da)	2006-02-27	Nukleinsyremolekyler kodende for proteiner, som medierer adhæsionen af Neisseria-celler til humane celler
DK0809653T3 (da)	2001-11-19	Helicobacter pylori-antigen
Folgueira et al.	2021	medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals. permissions@ oup. com
DE60021409D1 (de)	2005-08-25	Neurokinin b vorläufer aus menschlicher plazenta